NewslettersDermal Cell NewsEvaxion Receives FDA Fast-Track Designation for Personalized Cancer ImmunotherapyBy Laurisa Dohm - January 23, 2023068Evaxion Biotech A/S announced that the FDA has granted fast track designation for their personalized cancer therapy, EVX-01, in combination with KEYTRUDA® for patients with metastatic melanoma.[Evaxion Biotech A/S]Press Release